What if cancer isn’t unstoppable — but the immune system just isn’t fully awake? Scientists at the University of Southampton ...

A phase one study shows personalised T cell activation induced durable immune responses with manageable toxicity in patients with chronic lymphocytic leukaemia receiving targeted therapy.

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

Immunotherapy has transformed the field of medicine. In the context of cancer, immune cells become dysregulated and lose the ...

Durable reprogramming of human T cells may now be possible thanks to a new technique based on the CRISPRoff and CRISPRon methodology. Researchers from the Arc Institute, Gladstone Institutes, and the ...

T cells sit at the center of modern immunotherapy, yet many of the rules that govern their activation, differentiation, dysfunction (e.g., exhaustion), and ...

An engineered viral protein enhanced the anticancer function of T cells in mice, suggesting a new strategy to improve immunotherapy. Courtney and his team sought to exploit this property of TIP to ...

Researchers from the Keck School of Medicine of USC have developed a new type of chimeric antigen receptor (CAR) T cell that elicits a more controlled immune response to cancer in mice—effectively ...

Press ReleaseIB [email protected] Bracco Enters Cell Therapy Manufacturing with Cell Selection and Activation TechnologiesTechnology based on Bracco’s clinically validated ...